

Vitaly Margulis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189884/publications.pdf>

Version: 2024-02-01

361
papers

14,227
citations

20797

60
h-index

29127

104
g-index

370
all docs

370
docs citations

370
times ranked

10037
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. <i>Cancer</i> , 2009, 115, 1224-1233.	2.0	943
2	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	9.4	791
3	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. <i>European Urology</i> , 2012, 62, 100-114.	0.9	349
4	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	9.4	310
5	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 612-618.	0.8	260
6	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. <i>Cancer</i> , 2010, 116, 3127-3134.	2.0	208
7	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	0.9	201
8	Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. <i>Journal of Urology</i> , 2009, 182, 900-906.	0.2	200
9	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. <i>Cell Metabolism</i> , 2018, 28, 793-800.e2.	7.2	193
10	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 818-825.	0.9	188
11	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. <i>Journal of Urology</i> , 2009, 181, 2482-2489.	0.2	186
12	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. <i>Cancer</i> , 2010, 116, 3378-3388.	2.0	183
13	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2010, 184, 453-458.	0.2	182
14	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. <i>European Urology</i> , 2012, 61, 245-253.	0.9	168
15	The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. <i>European Urology</i> , 2011, 59, 912-918.	0.9	167
16	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. <i>European Urology</i> , 2009, 56, 1-9.	0.9	161
17	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. <i>BJU International</i> , 2009, 103, 307-311.	1.3	160
18	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 137ra75.	5.8	159

#	ARTICLE	IF	CITATIONS
19	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 94-98.	0.2	157
20	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. <i>European Urology</i> , 2010, 57, 1072-1079.	0.9	155
21	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2010, 57, 575-581.	0.9	154
22	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014, 120, 1794-1799.	2.0	154
23	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. <i>Journal of Urology</i> , 2013, 189, 1662-1669.	0.2	152
24	Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease. <i>Clinical Cancer Research</i> , 2006, 12, 7369-7373.	3.2	144
25	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	3.0	144
26	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. <i>European Urology</i> , 2009, 56, 512-519.	0.9	143
27	Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. <i>European Urology</i> , 2011, 60, 776-783.	0.9	135
28	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	0.9	134
29	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	1.3	128
30	Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. <i>BJU International</i> , 2010, 105, 1672-1677.	1.3	115
31	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. <i>European Urology</i> , 2014, 66, 584-592.	0.9	100
32	A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. <i>Nature Communications</i> , 2015, 6, 8699.	5.8	99
33	Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors. <i>Urology</i> , 2005, 65, 877-881.	0.5	98
34	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	0.9	98
35	Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. <i>Cancer</i> , 2008, 112, 1480-1488.	2.0	95
36	Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 181, 2044-2051.	0.2	94

#	ARTICLE	IF	CITATIONS
37	Multifocal Carcinoma In Situ of the Upper Tract Is Associated With High Risk of Bladder Cancer Recurrence. <i>European Urology</i> , 2012, 61, 1069-1070.	0.9	94
38	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph node density. <i>BJU International</i> , 2009, 103, 302-306.	1.3	93
39	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	0.9	93
40	Survivin: a promising biomarker for detection and prognosis of bladder cancer. <i>World Journal of Urology</i> , 2008, 26, 59-65.	1.2	92
41	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 252-258.	0.8	88
42	Nomograms for Bladder Cancer. <i>European Urology</i> , 2008, 54, 41-53.	0.9	87
43	Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers. <i>Clinical Cancer Research</i> , 2008, 14, 3785-3791.	3.2	79
44	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
45	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	0.8	77
46	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. <i>Journal of Urology</i> , 2014, 192, 1050-1056.	0.2	76
47	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 690-698.	0.2	76
48	Inventory of prostate cancer predictive tools. <i>Current Opinion in Urology</i> , 2008, 18, 279-296.	0.9	73
49	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. <i>Urology</i> , 2009, 73, 142-146.	0.5	73
50	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 716-723.	0.8	73
51	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2011, 108, 1286-1291.	1.3	71
52	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.2	69
53	Renal cell carcinoma clinically involving adjacent organs. <i>Cancer</i> , 2007, 109, 2025-2030.	2.0	68
54	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. <i>European Urology</i> , 2013, 64, 465-471.	0.9	68

#	ARTICLE	IF	CITATIONS
55	Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 947-952.	0.9	67
56	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 91-100.	0.4	67
57	Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. <i>Journal of Endourology</i> , 2017, 31, 1164-1169.	1.1	67
58	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. <i>Journal of Urology</i> , 2015, 194, 21-29.	0.2	66
59	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. <i>European Urology</i> , 2020, 78, 209-220.	0.9	66
60	Stereotactic Ablative Radiation Therapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375.	0.4	65
61	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. <i>International Journal of Urology</i> , 2012, 19, 1060-1066.	0.5	64
62	Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease. <i>Cancer</i> , 2009, 115, 2355-2360.	2.0	62
63	Acute histologic effects of temperature-based radiofrequency ablation on renal tumor pathologic interpretation. <i>Urology</i> , 2004, 64, 660-663.	0.5	61
64	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. <i>European Urology</i> , 2013, 63, 244-251.	0.9	61
65	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61
66	Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. <i>Urology</i> , 2009, 74, 1070-1074.	0.5	58
67	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.2	58
68	Location of Extrarenal Tumor Extension Does Not Impact Survival of Patients With pT3a Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1878-1882.	0.2	57
69	Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. <i>BJU International</i> , 2007, 100, 1235-1239.	1.3	57
70	Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 619-628.	0.9	57
71	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 187, 845-851.	0.2	57
72	Redefining pT3 renal cell carcinoma in the modern era. <i>Cancer</i> , 2007, 109, 2439-2444.	2.0	55

#	ARTICLE	IF	CITATIONS
73	New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. <i>BJU International</i> , 2008, 101, 675-683.	1.3	55
74	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978.	0.5	55
75	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	0.8	55
76	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	0.7	53
77	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 199, 1440-1445.	0.2	53
78	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. <i>World Journal of Urology</i> , 2011, 29, 495-501.	1.2	50
79	<sc>Ki67</sc> is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. <i>BJU International</i> , 2014, 113, 668-673.	1.3	49
80	Predicting survival after radical cystectomy for bladder cancer. <i>BJU International</i> , 2008, 102, 15-22.	1.3	48
81	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	0.9	48
82	Cytokine Response to Surgical Stress: Comparison of Pure Laparoscopic, Hand-Assisted Laparoscopic, and Open Nephrectomy. <i>Journal of Endourology</i> , 2005, 19, 1140-1145.	1.1	46
83	Surgical Management of Renal Cell Carcinoma. <i>Seminars in Interventional Radiology</i> , 2014, 31, 027-032.	0.3	46
84	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. <i>Journal of Urology</i> , 2017, 197, 1208-1213.	0.2	45
85	Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder. <i>Journal of Urology</i> , 2007, 177, 1163-1168.	0.2	44
86	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. <i>BJU International</i> , 2011, 108, E304-E309.	1.3	44
87	Upper tract urothelial carcinoma: Impact of time to surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 266-272.	0.8	44
88	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvic/Calyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. <i>European Urology</i> , 2012, 62, 224-231.	0.9	44
89	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e25-e36.	0.9	44
90	A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. <i>Pediatric Blood and Cancer</i> , 2014, 61, 446-451.	0.8	43

#	ARTICLE	IF	CITATIONS
91	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. <i>Journal of Urology</i> , 2017, 197, 287-295.	0.2	43
92	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 924-931.	0.8	42
93	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404.	2.6	42
94	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2014, 114, 56-61.	1.3	41
95	Reconstruction of Large Perineal and Pelvic Wounds Using Gracilis Muscle Flaps. <i>Annals of Surgical Oncology</i> , 2015, 22, 3738-3744.	0.7	40
96	Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double-Strand Break Repair Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2366-2373.	1.1	39
97	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 5-11.	1.2	39
98	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	0.8	39
99	Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. <i>BJU International</i> , 2016, 117, E87-94.	1.3	39
100	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017, 35, 355-365.	1.2	39
101	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493.	0.2	38
102	Oncologic outcomes of partial versus radical nephrectomy for unilateral Wilms Tumor. <i>Pediatric Blood and Cancer</i> , 2012, 58, 898-904.	0.8	37
103	Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2013, 81, 581-586.	0.5	37
104	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
105	Laparoscopic and Open Retroperitoneal Lymph-Node Dissection for Clinical Stage I Nonseminomatous Germ-Cell Testis Tumors. <i>Journal of Endourology</i> , 2006, 20, 627-631.	1.1	36
106	Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 388.e1-388.e9.	0.8	36
107	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.4	36
108	Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 1101-1108.	0.2	36

#	ARTICLE	IF	CITATIONS
109	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.2	35
110	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.2	35
111	RETROGRADE RENAL COOLING DURING RADIO FREQUENCY ABLATION TO PROTECT FROM RENAL COLLECTING SYSTEM INJURY. <i>Journal of Urology</i> , 2005, 174, 350-352.	0.2	34
112	Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 292.e1-292.e9.	0.8	34
113	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 251-259.	1.2	33
114	Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. <i>EBioMedicine</i> , 2020, 51, 102526.	2.7	33
115	The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 308-314.	1.0	32
116	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. <i>Urology</i> , 2009, 73, 337-341.	0.5	32
117	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2011, 77, 861-866.	0.5	31
118	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	1.3	31
119	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	0.8	31
120	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e585-e594.	0.9	31
121	Effect of Testicular Germ Cell Tumor Therapy on Renal Function. <i>Urology</i> , 2012, 80, 641-648.	0.5	29
122	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.2	29
123	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	1.3	29
124	SPARC is a key mediator of TGF β -induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1926-1938.	2.0	29
125	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	0.2	28
126	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	0.9	27

#	ARTICLE	IF	CITATIONS
127	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2015, 85, 876-882.	0.5	27
128	Multi-institutional Evaluation of Upper Urinary Tract Biopsy Using Backloaded Cup Biopsy Forceps, a Nitinol Basket, and Standard Cup Biopsy Forceps. <i>Urology</i> , 2018, 117, 89-94.	0.5	27
129	Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). <i>Journal of Urology</i> , 2021, 206, 568-576.	0.2	27
130	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e9-167.e16.	0.8	26
131	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. <i>BJU International</i> , 2017, 119, 268-275.	1.3	26
132	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. <i>Journal of Urology</i> , 2017, 198, 810-816.	0.2	26
133	Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e739-e753.	0.9	26
134	Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. <i>Advances in Anatomic Pathology</i> , 2021, 28, 251-257.	2.4	26
135	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87.	0.2	26
136	Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?. <i>European Urology</i> , 2008, 54, 489-492.	0.9	25
137	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 673-683.	0.9	25
138	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. <i>Urology</i> , 2015, 86, 1146-1152.	0.5	25
139	Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. <i>Cancer Biology and Therapy</i> , 2015, 16, 657-661.	1.5	25
140	Determinants of renal cell carcinoma invasion and metastatic competence. <i>Nature Communications</i> , 2021, 12, 5760.	5.8	25
141	Type III Transforming Growth Factor- β (TGF- β) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF- β Signaling Pathway. <i>Clinical Cancer Research</i> , 2008, 14, 5722-5730.	3.2	24
142	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28.	0.8	24
143	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e1-268.e7.	0.8	24
144	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15-year experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43.	0.6	24

#	ARTICLE	IF	CITATIONS
145	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	0.8	24
146	Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1662-1667.	0.2	23
147	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	0.2	22
148	Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2015, 121, 43-50.	2.0	22
149	Tumour and patient factors in renal cell carcinoma towards personalized therapy. <i>Nature Reviews Urology</i> , 2015, 12, 253-262.	1.9	22
150	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	1.2	22
151	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 12-21.e1.	0.9	22
152	Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 31508-31519.	0.8	22
153	Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair α -Analysis (ROBUUST Collaborative Group). <i>Journal of Endourology</i> , 2022, 36, 752-759.	1.1	22
154	The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Endourology</i> , 2011, 25, 775-779.	1.1	21
155	Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e17-37.e23.	0.8	21
156	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	0.8	21
157	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 757-770.	1.9	21
158	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 758-764.	0.8	21
159	Prognostic role of the systemic immune inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	2.0	21
160	Assessment of Hematuria. <i>Medical Clinics of North America</i> , 2011, 95, 153-159.	1.1	20
161	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2015, 33, 1165-1171.	1.2	20
162	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.4	20

#	ARTICLE	IF	CITATIONS
163	What is the role of nephrectomy following complete response to checkpoint inhibitors?. Urology Case Reports, 2018, 18, 60-63.	0.1	20
164	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	0.9	20
165	Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. Journal of Urology, 2014, 191, 1485-1490.	0.2	19
166	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2018, 115, 119-124.	0.5	19
167	The Role of Systemic Chemotherapy in Management of Upper Tract Urothelial Cancer. Current Urology Reports, 2013, 14, 94-101.	1.0	18
168	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	0.5	18
169	Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World Journal of Urology, 2014, 32, 615-622.	1.2	18
170	Therapeutic strategies for upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 765-774.	1.1	18
171	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. European Urology Oncology, 2019, 2, 691-698.	2.6	18
172	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoablative Nephrectomy with Thrombectomy. European Urology Focus, 2020, 6, 104-111.	1.6	18
173	Robotic Nephroureterectomy <i>vs</i> Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. Journal of Endourology, 2021, 35, 312-318.	1.1	18
174	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. Advances in Radiation Oncology, 2021, 6, 100692.	0.6	18
175	Multiple vesical calculi and complete vaginal vault prolapse. American Journal of Obstetrics and Gynecology, 2003, 189, 884-885.	0.7	17
176	Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: Identification of lupus anticoagulants. Urology, 2005, 66, 830-834.	0.5	17
177	Cytoablative nephrectomy in metastatic renal cell carcinoma. Current Opinion in Urology, 2008, 18, 474-480.	0.9	17
178	Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. European Urology, 2012, 62, e27-e29.	0.9	17
179	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. Clinical Cancer Research, 2021, 27, 4794-4806.	3.2	17
180	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 409-421.	0.8	17

#	ARTICLE	IF	CITATIONS
181	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e9-166.e13.	0.8	17
182	Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Canadian Journal of Urology</i> , 2015, 22, 7865-75.	0.0	17
183	EFFECT OF WARMED, HUMIDIFIED INSUFFLATION GAS AND ANTI-INFLAMMATORY AGENTS ON CYTOKINE RESPONSE TO LAPAROSCOPIC NEPHRECTOMY: PORCINE MODEL. <i>Journal of Urology</i> , 2005, 174, 1452-1456.	0.2	16
184	APPLICATION OF NOVEL HEMOSTATIC AGENT DURING LAPAROSCOPIC PARTIAL NEPHRECTOMY. <i>Journal of Urology</i> , 2005, 174, 761-764.	0.2	16
185	Carcinoma in situ of the Upper Urinary Tract Treated with Radical Nephroureterectomy – Results from a Multicenter Study. <i>European Urology</i> , 2008, 54, 961-963.	0.9	16
186	Pre-surgical targeted molecular therapy in renal cell carcinoma. <i>BJU International</i> , 2009, 103, 150-153.	1.3	16
187	Penile Cancer: Management of Regional Lymphatic Drainage. <i>Urologic Clinics of North America</i> , 2010, 37, 411-419.	0.8	16
188	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	0.5	16
189	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , 2017, 119, 234-238.	1.3	16
190	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e903-e908.	0.9	16
191	Oncologic outcomes of radical nephroureterectomy (RNU). <i>Translational Andrology and Urology</i> , 2020, 9, 1841-1852.	0.6	16
192	A renal cell carcinoma tumorgraft platform to advance precision medicine. <i>Cell Reports</i> , 2021, 37, 110055.	2.9	16
193	Single-stage Xi [®] robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	16
194	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	0.8	15
195	Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma. <i>BJU International</i> , 2017, 119, 741-747.	1.3	15
196	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	0.5	15
197	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e11-88.e18.	0.8	15
198	The Rho GTPase signalling pathway in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 83-91.	1.9	15

#	ARTICLE	IF	CITATIONS
199	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. <i>BJU International</i> , 2021, 128, 168-177.	1.3	15
200	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	1.3	14
201	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2016, 196, 321-326.	0.2	14
202	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	0.9	14
203	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235.	0.9	14
204	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251.	2.6	14
205	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. <i>BJU International</i> , 2020, 128, 57-64.	1.3	14
206	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. <i>Cancer</i> , 2020, 126, 4362-4370.	2.0	14
207	Need for upper urinary tract stenting in cases of ureteral orifice injury during laser enucleation of the prostate. <i>International Urology and Nephrology</i> , 2018, 50, 2173-2177.	0.6	13
208	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 617-625.	1.3	13
209	LBA26 PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR PATIENTS WITH HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA (HG UTUC): RESULTS FROM ECOG-ACRIN 8141. <i>Journal of Urology</i> , 2018, 199, .	0.2	13
210	Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry. <i>Journal of Urology</i> , 2022, , 101097JU00000000000002690.	0.2	13
211	Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 418.e9-418.e16.	0.8	12
212	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 1073-1080.	1.2	12
213	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	1.0	12
214	Is cytoreductive nephrectomy relevant in the immunotherapy era?. <i>Current Opinion in Urology</i> , 2019, 29, 526-530.	0.9	12
215	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 601.e17-601.e24.	0.8	12
216	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	3.2	12

#	ARTICLE	IF	CITATIONS
217	Role of cytoreductive nephrectomy in renal cell carcinoma. <i>Future Oncology</i> , 2009, 5, 859-869.	1.1	11
218	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	0.8	11
219	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	0.6	11
220	Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma. <i>Current Urology Reports</i> , 2018, 19, 82.	1.0	11
221	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 602.e11-602.e19.	0.8	11
222	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	1.3	11
223	Risk prediction in the management of small renal masses. <i>Current Opinion in Urology</i> , 2012, 22, 347-352.	0.9	10
224	Histologic Variants of Upper Tract Urothelial Carcinoma Do Not Affect Response to Adjuvant Chemotherapy After Radical Nephroureterectomy. <i>European Urology</i> , 2012, 62, e25-e26.	0.9	10
225	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 614-621.	0.7	10
226	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. <i>Urology</i> , 2016, 96, 44-53.	0.5	10
227	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1411-1419.	1.2	10
228	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1786-1793.	0.6	10
229	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 933.e7-933.e12.	0.8	10
230	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. <i>Bladder Cancer</i> , 2020, 6, 201-210.	0.2	10
231	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 737.e11-737.e16.	0.8	10
232	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	1.6	10
233	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	0.8	10
234	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. <i>Current Oncology Reports</i> , 2008, 10, 253-258.	1.8	9

#	ARTICLE	IF	CITATIONS
235	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	1.2	9
236	Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 105-118.	0.8	9
237	Metastatic Melanoma to the Bladder: Case Report and Review of the Literature. <i>Urology Case Reports</i> , 2017, 11, 33-36.	0.1	9
238	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	1.2	9
239	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206.	2.6	9
240	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2021, 39, 1977-1984.	1.2	9
241	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26.	0.8	8
242	Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma. <i>European Radiology</i> , 2018, 28, 124-132.	2.3	8
243	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18.	0.8	8
244	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	8
245	Upper tract urothelial carcinoma: special considerations. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 101-9.	0.3	8
246	OUTCOMES FOR PATIENTS WITH pT0 DISEASE AFTER RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA. <i>BJU International</i> , 2009, 103, 3-4.	1.3	7
247	In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 837-842.	1.1	7
248	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112.	1.2	7
249	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus â€“ Initial Experience Report and Literature Review. <i>Kidney Cancer</i> , 2019, 3, 71-77.	0.2	7
250	Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 145, 159-165.	0.5	7
251	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 15-33.	0.8	7
252	A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	7

#	ARTICLE	IF	CITATIONS
253	Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States. <i>JAMA Network Open</i> , 2021, 4, e2112813.	2.8	7
254	Vaginal Vault Fixation and Prevention of Enterocele Recurrence by High Midline Levator Myorrhaphy: Physical Examination and Questionnaire-Based Follow-Up. <i>European Urology</i> , 2001, 40, 648-651.	0.9	6
255	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. <i>Clinical Proteomics</i> , 2009, 5, 37-45.	1.1	6
256	Impact of Statin Use on Oncologic Outcomes of Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1134-1135.	0.9	6
257	Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e443-e450.	0.9	6
258	Editorial. Current Opinion in Urology, 2019, 29, 505-506.	0.9	6
259	Advancements in the clinical management of upper tract urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1051-1060.	1.1	6
260	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	0.8	6
261	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	1.2	6
262	Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e17-660.e25.	0.8	5
263	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	0.2	5
264	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1631-1637.	1.2	5
265	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1218.	1.0	5
266	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	0.6	5
267	Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 311-311.	0.8	5
268	Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 619-619.	0.8	5
269	Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study. <i>Cancers</i> , 2021, 13, 5935.	1.7	5
270	Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	5

#	ARTICLE	IF	CITATIONS
271	Update on staging controversies for locally advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2007, 7, 909-914.	1.1	4
272	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 676-681.	0.8	4
273	The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. Current Opinion in Urology, 2013, 23, 411-417.	0.9	4
274	Assessing treatment response after induction cystectomy in patients with carcinoma <i>in situ</i> of the urinary bladder: can post-induction random bladder biopsies be avoided?. Cytopathology, 2014, 25, 108-111.	0.4	4
275	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
276	Molecularly-driven precision medicine for advanced bladder cancer. World Journal of Urology, 2018, 36, 1749-1757.	1.2	4
277	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	0.8	4
278	Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy. Lancet Oncology, The, 2019, 20, 473-475.	5.1	4
279	Sex differences in upper tract urothelial carcinomas. Current Opinion in Urology, 2019, 29, 256-260.	0.9	4
280	Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e184-e186.	0.9	4
281	Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018 . European Urology, 2020, 78, e79-e80.	0.9	4
282	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, 51, 1149-1157.	0.6	4
283	A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate. Case Reports in Pathology, 2021, 2021, 1-8.	0.2	4
284	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2020, 38, 416-416.	0.8	4
285	Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. Canadian Journal of Urology, 2016, 23, 8334-41.	0.0	4
286	Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. Journal of Endourology, 2022, 36, 1070-1076.	1.1	4
287	Prognostic markers in renal cell carcinoma: A focus on the mammalian target of rapamycin™ pathway. Arab Journal of Urology Arab Association of Urology, 2012, 10, 110-117.	0.7	3
288	Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?. Journal of Adolescent and Young Adult Oncology, 2016, 5, 248-253.	0.7	3

#	ARTICLE	IF	CITATIONS
289	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 262-275.	1.8	3
290	Transesophageal Echocardiography Imaging of the Inferior Vena Cava and Hepatic Vein Masses. A&A Practice, 2019, 12, 295-297.	0.2	3
291	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	1.6	3
292	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	0.8	3
293	<p>The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States</p>. Cancer Management and Research, 2020, Volume 12, 9825-9836.	0.9	3
294	Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. Frontiers in Oncology, 2021, 11, 724682.	1.3	3
295	Size-focality-invasion in upper tract urothelial carcinoma (SFI-UTUC): A novel imaging-based score to predict survival outcomes.. Journal of Clinical Oncology, 2018, 36, 475-475.	0.8	3
296	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	0.9	3
297	Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 201.e1-201.e7.	0.8	3
298	Urinary retention after tension-free vaginal tape procedure: From incision to excision to complete urethrolisis. Urology, 2004, 64, 590.	0.5	2
299	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. Journal of Urology, 2017, 198, 1021-1026.	0.2	2
300	Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis. Clinical Genitourinary Cancer, 2019, 17, e768-e771.	0.9	2
301	The use of cytoreductive nephrectomy in patients with renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 405-411.	1.1	2
302	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. European Urology Open Science, 2020, 19, 16-19.	0.2	2
303	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World Journal of Urology, 2021, 39, 491-500.	1.2	2
304	Locally Advanced Kidney Cancer: A New Space for Immunotherapy?. European Urology Oncology, 2022, 5, 118-119.	2.6	2
305	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e15-788.e21.	0.8	2
306	Validation of testicular germ cell tumor staging in nationwide cancer registries. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e1-838.e6.	0.8	2

#	ARTICLE	IF	CITATIONS
307	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25.	0.8	2
308	Editorial Comment. <i>Journal of Urology</i> , 2012, 187, 806-806.	0.2	1
309	Rapid Progression of a Germ Cell Tumor Encasing the Inferior Vena Cava and Aorta following a Radical Orchiectomy. <i>Rare Tumors</i> , 2013, 5, 79-82.	0.3	1
310	MP77-09 FEASIBILITY OF OBTAINING BIOMARKER PROFILES FROM ENDOSCOPIC BIOPSY SPECIMENS IN UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS. <i>Journal of Urology</i> , 2014, 191, .	0.2	1
311	Cytoreductive nephrectomy. <i>Current Opinion in Urology</i> , 2019, 29, 540-541.	0.9	1
312	Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. <i>Lancet</i> 2020;395:1268-77. <i>European Urology</i> , 2021, 79, e28.	0.9	1
313	Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e129-e134.	0.9	1
314	Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center. <i>Urology</i> , 2021, . .	0.5	1
315	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 76-76.	0.2	1
316	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586.	0.8	1
317	The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 103.e1-103.e1.	0.8	1
318	Performance characteristics of 18F-Fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 390-390.	0.8	1
319	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 417-417.	0.8	1
320	Performance characteristics of 18F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection. <i>Canadian Urological Association Journal</i> , 2021, 16, E167-E172.	0.3	1
321	Urothelial carcinoma of the upper urinary tracts: current knowledge and future perspectives. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 348-9.	3.9	1
322	Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols?. <i>Current Urology</i> , 2007, 1, 24-27.	0.4	0
323	Editorial Comment. <i>Journal of Urology</i> , 2012, 187, 1182-1182.	0.2	0
324	Editorial Comment to Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity score-matched multicenter study. <i>International Journal of Urology</i> , 2014, 21, 1105-1105.	0.5	0

#	ARTICLE	IF	CITATIONS
325	Editorial Comment. Journal of Urology, 2014, 192, 688-688.	0.2	0
326	Editorial Comment from Dr Haddad and Dr Margulis to Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. International Journal of Urology, 2015, 22, 1022-1022.	0.5	0
327	Editorial. Current Opinion in Urology, 2015, 25, 357.	0.9	0
328	Editorial Comment to Spherical cap surface model: A novel method for predicting renal function after partial nephrectomy. International Journal of Urology, 2016, 23, 673-673.	0.5	0
329	Single nucleotide polymorphisms of the vascular endothelial growth factor receptor "a promising biomarker in metastatic renal cell carcinoma. BJU International, 2016, 118, 847-848.	1.3	0
330	EDITORIAL COMMENT. Urology, 2019, 129, 85.	0.5	0
331	Clinical outcomes of a cohort of patients with bulky, clinically node-positive bladder cancer undergoing radical cystectomy in the contemporary era. Canadian Urological Association Journal, 2020, 15, E286-E289.	0.3	0
332	The Changing Landscape of Upper Tract Urothelial Carcinoma Management. Urology, 2020, 145, 316-318.	0.5	0
333	Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).. Journal of Clinical Oncology, 2021, 39, 381-381.	0.8	0
334	Nephroureterectomy for Upper Tract Urothelial Carcinoma: Indications and Technique. , 2021, , 439-446.		0
335	AUAP-3 Urothelial carcinoma at the uretero-enteric junction : multi-center evaluation of oncologic outcomes after radical nephroureterctomy. Japanese Journal of Urology, 2011, 102, 94.	0.0	0
336	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2012, 30, 281-281.	0.8	0
337	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, TPS4678-TPS4678.	0.8	0
338	Utility of lymph node dissection for clinical node negative upper tract urothelial cell carcinoma: A multicenter study.. Journal of Clinical Oncology, 2018, 36, 474-474.	0.8	0
339	Cytoreductive Nephrectomy and Metastasectomy for Renal Cell Carcinoma. , 2019, , 299-311.		0
340	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 663-663.	0.8	0
341	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 651-651.	0.8	0
342	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, 599-599.	0.8	0

#	ARTICLE	IF	CITATIONS
343	The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 632-632.	0.8	0
344	Editorial Comment. Journal of Urology, 2019, 201, 1086-1086.	0.2	0
345	Tumor location does not limit percutaneous treatment of small renal masses with microwave ablation. Annals of Translational Medicine, 2019, 7, S231-S231.	0.7	0
346	Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.. Journal of Clinical Oncology, 2020, 38, 398-398.	0.8	0
347	Effect of increasing Medicaid coverage in Medicaid expansion states on stage at presentation for urologic malignancies.. Journal of Clinical Oncology, 2020, 38, 400-400.	0.8	0
348	Reply by Authors. Journal of Urology, 2020, 203, 697-698.	0.2	0
349	Gossypiboma manifesting as urachal mass. Reviews in Urology, 2016, 18, 239-241.	0.9	0
350	IS THERE A ROLE FOR RADIATION FOR PRIMARY KIDNEY TUMORS?. AUANews, 2019, 24, 4.	0.0	0
351	Differences between Upper Tract Urothelial Carcinoma and Bladder Cancer. AUANews, 2021, 26, 15-16.	0.0	0
352	Editorial Comment. Journal of Urology, 2020, 204, 536-536.	0.2	0
353	Optimizing oncologic outcomes in upper tract urothelial carcinoma. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2016, 68, 372-80.	3.9	0
354	Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.. Journal of Clinical Oncology, 2022, 40, 414-414.	0.8	0
355	Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.. Journal of Clinical Oncology, 2022, 40, 425-425.	0.8	0
356	Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.. Journal of Clinical Oncology, 2022, 40, 424-424.	0.8	0
357	Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients.. Journal of Clinical Oncology, 2022, 40, 525-525.	0.8	0
358	Role of preoperative albumin in predicting risk of postoperative complications in patients undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2022, 40, 416-416.	0.8	0
359	Routine Overnight Vital Signs Are Rarely Associated with Major Clinical Events in Patients Undergoing Radical Cystectomy: A Retrospective Cohort Study. Urology Practice, 2022, 9, 150-157.	0.2	0
360	Variability in prognostic models for localized renal cell carcinoma. Nature Reviews Urology, 2022, , .	1.9	0

#	ARTICLE	IF	CITATIONS
361	Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration. Bladder Cancer, 2022, , 1-12.	0.2	0